Results 61 to 70 of about 43,089 (386)

Impact of severe secondary tricuspid regurgitation on rest and exercise hemodynamics of patients with heart failure and a preserved left ventricular ejection fraction

Frontiers in Cardiovascular Medicine, 2023
BackgroundBoth secondary tricuspid regurgitation (STR) and heart failure with preserved ejection fraction (HFpEF) are relevant public health problems in the elderly population, presenting with potential overlaps and sharing similar risk factors. However,
Claudia Baratto, Sergio Caravita, Sergio Caravita, Giorgia Corbetta, Giorgia Corbetta, Davide Soranna, Antonella Zambon, Antonella Zambon, Céline Dewachter, Mara Gavazzoni, Francesca Heilbron, Michele Tomaselli, Noela Radu, Francesco Paolo Perelli, Francesco Paolo Perelli, Giovanni Battista Perego, Jean-Luc Vachiéry, Gianfranco Parati, Gianfranco Parati, Luigi P. Badano, Luigi P. Badano, Denisa Muraru, Denisa Muraru   +22 more
doaj   +1 more source

Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2020
Importance Patients with heart failure and preserved ejection fraction (HFpEF) are at high risk of mortality, hospitalizations, and reduced functional capacity and quality of life.
P. Armstrong, C. Lam, K. Anstrom, J. Ezekowitz, Adrian F. Hernandez, C. O'connor, B. Pieske, P. Ponikowski, Sanjiv J. Shah, S. Solomon, A. Voors, Lilin She, Vanja Vlajnic, F. Carvalho, L. Bamber, R. Blaustein, L. Roessig, J. Butler   +17 more
semanticscholar   +1 more source

Non-invasive assessment of HFpEF in mouse models: current gaps and future directions

BMC Medicine, 2022
Heart failure (HF) with preserved ejection fraction (HFpEF) prevalence is increasing, and large clinical trials have failed to reduce mortality. A major reason for this outcome is the failure to translate results from basic research to the clinics ...
M. Villalba-Orero, P. García-Pavía, E. Lara-Pezzi   +2 more
semanticscholar   +1 more source

Potential Mechanisms of Epicardial Adipose Tissue Influencing HeartFailure with Preserved Ejection Fraction

Reviews in Cardiovascular Medicine
Heart failure (HF) is the predominant terminal stage and the leading cause ofmortality in cardiac disease. Heart failure with preserved ejection fraction(HFpEF) affects roughly 50% of HF patients globally.
Qiuxuan Li, Ur Rehman Muhib, Xiaoteng Ma, Zaiqiang Liu, Fei Gao, Zhijian Wang   +5 more
doaj   +1 more source

Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A phase 2, randomized, sham-controlled trial [PDF]

, 2018
Background -In non-randomized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), less symptoms, and greater quality of life and exercise capacity in ...
Basuray, Anupam, Burkhoff, Daniel, Fail, Peter S., Feldman, Ted, Forde-McLean, Rhondalyn, Hummel, Scott L., Kahwash, Rami, Kaye, David M., Lilly, Scott, Litwin, Sheldon, Massaro, Joseph M., Mauri, Laura, Nielsen, Christopher D., Penicka, Martin, Petrie, Mark C., Ricciardi, Mark J., Shah, Sanjiv J., van der Harst, Pim   +17 more
core   +1 more source

Patient Perspectives on the Burden of Heart Failure with Preserved Ejection Fraction in a US Commercially Insured and Medicare Advantage Population: A Survey Study

Patient Preference and Adherence, 2023
Chi Nguyen,1 Luke Bamber,2 Vincent J Willey,1 Thomas Evers,2 Thomas P Power,3 Judith J Stephenson1 1HealthCore, Inc., Wilmington, DE, USA; 2Bayer AG, Wuppertal, 42096, Germany; 3AIM Specialty Health, Chicago, IL, USACorrespondence: Chi Nguyen, HealthCore,
Nguyen C, Bamber L, Willey VJ, Evers T, Power TP, Stephenson JJ   +5 more
doaj  

Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials

European Heart Journal
Background and Aims In the STEP-HFpEF trial programme, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).
Sanjiv J. Shah, Kavita Sharma, Barry A. Borlaug, Javed Butler, M. Davies, D. Kitzman, Mark C. Petrie, Subodh Verma, Shachi Patel, Khaja M. Chinnakondepalli, M. N. Einfeldt, T. J. Jensen, S. Rasmussen, Rabea Asleh, Tuvia Ben-Gal, M. Kosiborod   +15 more
semanticscholar   +1 more source

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

Cardiovascular Diabetology, 2021
Background Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidity in heart ...
D. Bode, L. Semmler, P. Wakula, N. Hegemann, U. Primessnig, N. Beindorff, David Powell, R. Dahmen, H. Ruetten, Christian Oeing, A. Alogna, D. Messroghli, B. Pieske, F. Heinzel, F. Hohendanner   +14 more
semanticscholar   +1 more source

Improving Postdischarge Outcomes in Acute Heart Failure [PDF]

, 2018
The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P., Antohi, Elena-Laura, Butler, Javed, Chioncel, Ovidiu, Collins, Sean P., Iliescu, Vlad Anton, Maggioni, Aldo P., Mebazaa, Alexandre, Pang, Peter S.   +8 more
core   +1 more source

Heart failure with preserved ejection fraction: A short review of diagnosis and management [PDF]

КардиоСоматика
Around 64 million persons in the world have heart failure (HF). HF patients with left ventricle ejection fraction (LVEF) of ≥50% are classified as having HF with preserved ejection fraction (HFpEF).
Sidhi Laksono, Prita Saskya Prameswari
doaj   +1 more source